tiprankstipranks
Trending News
More News >
Mitsubishi Research Institute (JP:3636)
:3636
Japanese Market

Mitsubishi Research Institute (3636) AI Stock Analysis

Compare
1 Followers

Top Page

JP:3636

Mitsubishi Research Institute

(3636)

Select Model
Select Model
Select Model
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
,
Outperform 77 (OpenAI - 5.2)
Rating:77Outperform
Price Target:
¥5,221.00
▲(7.43% Upside)
Action:ReiteratedDate:02/07/26
The score is driven primarily by strong financial performance (profitability and a very low-leverage balance sheet) and an attractive valuation (low P/E with a solid dividend). Technicals are supportive but less decisive due to mixed momentum signals, and declining free cash flow trends temper the otherwise solid fundamentals.
Positive Factors
Low Leverage / Strong Balance Sheet
Very low leverage gives MRI durable financial flexibility: it can fund project-backed IT and consulting investments, maintain dividends, and withstand public-sector budget timing variability. The conservative capital structure reduces refinancing risk and supports strategic optionality over months.
Consistent Revenue Growth & Margin Improvement
Sustained revenue growth coupled with rising gross margin signals effective pricing and cost control across consulting and systems work. Recurring client relationships and follow-on implementation work can continue to underpin steady fee revenue and margin durability over the medium term.
Healthy Operating Cash Generation
Stable operating cash flow, supported by positive net margin (5.26%), indicates the core business converts earnings to cash reliably. That cash flow supports reinvestment in IT services, working capital for multi-month projects, and sustainable shareholder distributions despite cyclical timing of engagements.
Negative Factors
Declining Free Cash Flow Conversion
A drop in free cash flow growth and a falling FCF-to-net-income ratio weakens the firm's ability to fund capex, strategic hires, or acquisitions from internal cash. Over the medium term this can constrain reinvestment into scalable IT offerings and reduce flexibility on shareholder returns.
Softening Return on Equity
A declining ROE implies the company is generating lower returns from shareholders' capital, which can indicate reduced operating leverage or capital allocation inefficiency. Persistently softer ROE may limit long-term shareholder value creation versus peers in the consulting/IT services space.
Modest Net Margin
Net margins around mid-single digits leave limited buffer for cost shocks or pricing pressure in a competitive consulting market. Given project-based revenue volatility and competition for implementation work, sustaining or expanding bottom-line profitability could be challenging without continued efficiency gains.

Mitsubishi Research Institute (3636) vs. iShares MSCI Japan ETF (EWJ)

Mitsubishi Research Institute Business Overview & Revenue Model

Company DescriptionMitsubishi Research Institute, Inc. provides think tank, consulting, and IT services to government agencies, financial institutions, and private companies in Japan. Its service solutions include management consulting, digital innovation, financial innovation, environment/energy, healthcare/wellness, regional revitalization, next-generation infrastructure, science/safety, nuclear safety, economy/society/R&D, project case, and public sector orders. Mitsubishi Research Institute, Inc. has a partnership with ForePaaS SAS to deliver cloud-native data intensive solutions in Japan. The company was founded in 1970 and is headquartered in Tokyo, Japan.
How the Company Makes MoneyMRI primarily earns revenue by delivering fee-based services and solutions to public and private clients. Key revenue streams include: (1) Research and consulting fees: the company conducts commissioned research, policy studies, surveys, economic/industry analysis, and strategic consulting engagements. These projects are typically contracted by government ministries/local governments and by corporations, with revenue recognized based on project delivery/contract terms. (2) System and IT-related services: MRI’s group also generates revenue from providing IT/system-related services connected to its consulting and research work, such as designing, developing, and supporting information systems and other implementation services for clients. (3) Recurring/continuing client relationships: MRI’s earnings are supported by repeat engagements where research/strategy work leads into implementation, operational support, or follow-on studies. Specific material partnerships, customer concentration, or segment-level revenue breakdowns are not available in the provided context and are therefore null.

Mitsubishi Research Institute Financial Statement Overview

Summary
Strong overall fundamentals: revenue grew 4.05% with improved gross margin (24.91%) and solid profitability (net margin 5.26%). Balance sheet strength is a key positive with very low leverage (debt-to-equity 0.014), though ROE has softened. Main risk area is cash conversion, as free cash flow growth and FCF-to-net-income have declined despite healthy operating cash flow.
Income Statement
85
Very Positive
Mitsubishi Research Institute has demonstrated consistent revenue growth with a 4.05% increase in the latest year, following a recovery from a slight dip the previous year. The gross profit margin has improved to 24.91%, indicating efficient cost management. Net profit margin stands at 5.26%, reflecting solid profitability. The EBIT and EBITDA margins have also shown positive trends, enhancing operational efficiency.
Balance Sheet
78
Positive
The company maintains a strong balance sheet with a low debt-to-equity ratio of 0.014, indicating minimal leverage and financial stability. The equity ratio is robust, highlighting a strong equity base. However, the return on equity has slightly decreased, suggesting room for improvement in generating returns from shareholders' equity.
Cash Flow
72
Positive
Operating cash flow remains healthy, but there has been a significant decline in free cash flow growth, which could impact future investments. The operating cash flow to net income ratio is stable, indicating good cash generation relative to net income. However, the free cash flow to net income ratio has decreased, suggesting potential challenges in converting profits into free cash flow.
BreakdownSep 2025Sep 2024Sep 2023Sep 2022Sep 2021
Income Statement
Total Revenue121.46B115.36B122.13B116.62B103.03B
Gross Profit30.26B27.13B27.72B28.07B24.50B
EBITDA11.48B10.81B12.44B12.78B10.47B
Net Income6.39B5.00B6.29B7.71B5.01B
Balance Sheet
Total Assets131.00B121.90B120.27B116.44B101.57B
Cash, Cash Equivalents and Short-Term Investments30.31B30.93B25.23B33.16B29.40B
Total Debt1.04B1.11B2.09B3.53B4.93B
Total Liabilities49.65B45.52B45.88B45.28B37.73B
Stockholders Equity71.92B67.63B65.80B63.05B56.28B
Cash Flow
Free Cash Flow2.81B12.18B3.09B7.94B2.30B
Operating Cash Flow6.42B13.54B5.70B9.26B3.25B
Investing Cash Flow-4.00B-2.91B-2.41B-6.65B-1.97B
Financing Cash Flow-3.01B-4.94B-6.20B-3.85B-4.62B

Mitsubishi Research Institute Technical Analysis

Technical Analysis Sentiment
Negative
Last Price4860.00
Price Trends
50DMA
4923.60
Negative
100DMA
4922.10
Negative
200DMA
4840.34
Negative
Market Momentum
MACD
-87.08
Positive
RSI
37.09
Neutral
STOCH
22.22
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For JP:3636, the sentiment is Negative. The current price of 4860 is above the 20-day moving average (MA) of 4788.75, below the 50-day MA of 4923.60, and above the 200-day MA of 4840.34, indicating a bearish trend. The MACD of -87.08 indicates Positive momentum. The RSI at 37.09 is Neutral, neither overbought nor oversold. The STOCH value of 22.22 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for JP:3636.

Mitsubishi Research Institute Peers Comparison

Overall Rating
UnderperformOutperform
Sector (61)
Financial Indicators
Name
Overall Rating
Market Cap
P/E Ratio
ROE
Dividend Yield
Revenue Growth
EPS Growth
77
Outperform
¥72.83B7.463.28%5.28%28.90%
76
Outperform
¥151.48B14.812.30%13.82%37.07%
75
Outperform
¥147.83B9.3411.52%2.76%4.00%38.72%
66
Neutral
¥169.13B15.9918.89%2.78%11.90%60.66%
65
Neutral
¥30.97B10.7510.34%4.82%-3.03%38.83%
61
Neutral
$37.18B12.37-10.20%1.83%8.50%-7.62%
* Technology Sector Average
Performance Comparison
Ticker
Company Name
Price
Change
% Change
JP:3636
Mitsubishi Research Institute
4,600.00
-206.18
-4.29%
JP:9682
DTS
1,064.00
26.58
2.56%
JP:9715
transcosmos
3,945.00
764.18
24.02%
JP:4725
CAC Holdings Corporation
1,834.00
-90.42
-4.70%
JP:2317
Systena Corporation
418.00
63.96
18.07%

Mitsubishi Research Institute Corporate Events

Mitsubishi Research Institute Posts Profit Surge but Keeps Cautious Full-Year Outlook
Feb 5, 2026

Mitsubishi Research Institute reported a strong rebound in earnings for the quarter ended December 31, 2025, with net sales rising 11.5% year on year to ¥30.9 billion and profit attributable to owners of parent surging 165.6% to ¥2.63 billion, driving basic earnings per share up to ¥167.27. The company also strengthened its financial position, as the equity-to-asset ratio improved to 59.0%, while it kept its full-year forecasts for the fiscal year ending September 30, 2026 unchanged, projecting essentially flat net sales and a modest decline in profits, and reaffirmed plans to maintain the annual dividend at ¥165 per share, signaling stability for shareholders despite expectations of lower profitability ahead.

The most recent analyst rating on (JP:3636) stock is a Buy with a Yen5341.00 price target. To see the full list of analyst forecasts on Mitsubishi Research Institute stock, see the JP:3636 Stock Forecast page.

Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.Date of analysis: Feb 07, 2026